Journal
PEDIATRIC BLOOD & CANCER
Volume 68, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/pbc.28949
Keywords
acquired autoimmune thrombotic thrombocytopenic purpura; hereditary thrombotic thrombocytopenic purpura; neonatal hyperbilirubinemia; stroke
Categories
Ask authors/readers for more resources
This article describes the presentation, diagnosis, and treatment of infants and children with hereditary and acquired autoimmune thrombotic thrombocytopenic purpura (TTP). Plasma and recombinant ADAMTS13 are effective treatments for exacerbations, while plasma exchange and immunosuppression are common for acquired TTP, with caplacizumab emerging as a potential replacement for plasma exchange.
We describe how infants and children with hereditary and acquired autoimmune thrombotic thrombocytopenic purpura (TTP) initially present and how they can be promptly diagnosed and effectively managed. These are uncommon disorders that are commonly misdiagnosed and can be rapidly fatal. TTP is caused by a severe deficiency of the plasma protease, A disintegrin and Metalloprotease with a ThromboSpondin type 1 motif, member 13 (ADAMTS13). Measurement of ADAMTS13 activity is becoming easily accessible. A common presentation of hereditary TTP is neonatal severe hemolysis and hyperbilirubinemia. However, the median age of diagnosis is not until 5.5 years. Plasma is effective treatment for exacerbations and for prophylaxis. Plasma may be replaced by recombinant ADAMTS13 when it becomes available. Acquired TTP is more frequent in older children, in whom it is more common in girls and is commonly associated with systemic lupus erythematosus. For acquired TTP, plasma exchange and immunosuppression are the current treatment for acute episodes; caplacizumab is now commonly used in adults and may replace plasma exchange.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available